Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole and probiotics in functional flatulence
IRCT20220916055971N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in abdominal bloating and Functional abdominal distension (FAD) comparing Metronidazole followed by FamiLact with FamiLact alone (2 arms). Primary endpoint: Abdominal bloating. Started May 2023; status: completed.
02
Drugs
metronidazoleFamiLact
03
Conditions
abdominal bloatingFunctional abdominal distension (FAD)
Beyond the preview
Go deeper on IRCT20220916055971N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220916055971N1.